Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — JMM Investor Lunch February 2026
15 slides from Neuroscientific Biopharmaceuticals's conference presentation, Feb 16, 2026
Slide 1: Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs
ASX: NSB Patented Stem Cell Solutions for For personal use only Complex Auto-Immune Disorders & Unmet Needs Nathan Smith | Chief Executive Officer JMM Investor Lunch | February 2026
Slide 2: Disclaimers
Disclaimers Presentation Information Forward Looking Statements This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) This presentation contains certain forward-looking statements that are based on the based on information available to it as at the date of this pre
Slide 3: Investment Highlights
Investment Highlights 01 02 03 04 For personal use only Robust Profile & Strong Patented StemSmart Proven Clinical Secure Supply Chain & Balance Sheet Tech Platform Safety & Efficacy Commercialisation Path $43.2M market cap1 with Proprietary manufacturing Strong safety profile and 78% Expanded manuf
Slide 4: Company Overview
Company Overview Corporate Share Information Capital Structure & Cash On Hand As at 11 February 2026 ORDINARY SHARES PERFORMANCE SHARES OPTIONS SHARE PRICE A$0.13 CAPITAL 332.6 million 57.1 million 48.25 million For personal use only MARKET CAPITALISATION ~A$43.2 million CASH ~$6.4 million (31/12/25
Slide 5: Strength in Leadership & Advisory
Strength in Leadership & Advisory ROB MCKENZIE DR ANTON UVAROV LL.B; B.Juris, FAICD PhD, MBA NON-EXECUTIVE CHAIRMAN NON-EXECUTIVE DIRECTOR • Lawyer with over 35 years’ experience in corporate and • Significant healthcare industry experience with a focus on neuroscience commercial transactions, restr
Slide 6: New Clinical & Scientific Advisory Board
New Clinical & Scientific Advisory Board 1 PROF CATHERINE COLE DR MARIAN STURM MBBS, FRACP, FRCPA FFSc (RCPA), PhD, MSc, BSc Hons CHIEF MEDICAL OFFICER CHIEF SCIENTIFIC OFFICER • 35 years experience in clinical paediatric haematology, oncology, • Expert with 40 years' experience in research, operati
Slide 7: Introducing StemSmart
Introducing StemSmart The StemSmart MSC product is potent, efficacious and safe1 StemSmart is a global patented technology Initial Target Indications resulting in activated MSC, differentiated from For personal use only others in product class Refractory Crohn’s Disease (Life-Threatening) • Unrespon
Slide 8: Special Access Program – StemSmart
Special Access Program – StemSmart Special Access Scheme (SAS) – Demonstrating a “Clinical Response” and the Path to Phase 2 What has been achieved? What does this mean for NSB? For personal use only NSB is already treating patients with Fistulising Crohn’s Confirms that StemSmart shows a meaningful
Slide 9: Product Pipeline & Market Size
Product Pipeline & Market Size Key Clinical Targets (StemSmartTM Addressable Markets) Forecast Global Market Increase in Market • Need for more effective treatments with less side effects US$13.8 billion Crohn’s • Require additional treatment option for patients who have failed By 20261 53% For pers
Slide 10: Key Milestones
ASX Announcement – “Successful Clinical Results Key Milestones Achieved Under Special Access Program” (13 January 2026) Crohn’s Disease - StemSmart 2026 2027 2028 2029 2030 2031 SAS Program – Fistulising Crohn’s Disease (Commenced June 2025) For personal use only Phase 2 Start-up Activities Phase 2
Slide 11: Securing the StemSmart Supply Chain
Securing the StemSmart Supply Chain Partnership with Q-Gen Cell Therapeutics1 Tech transfer has been initiated for NSB’s patented manufacturing process with targeting Phase 2 clinical trial supply by 2H CY2026. For personal use only Q-Gen has a 13-cleanroom facility that has been licensed by the TGA
Slide 12: The Vision for Stem Cell Therapies
The Vision for Stem Cell Therapies… Global Crohn’s Solution Over 6 Million people are living with Crohn’s globally (over 1 million in US alone) with for Unmet Medical Need over 30% not responding to conventional treatment including blockbuster biologics. Patented Platform For personal use only Signi
Slide 13: Contact
ASX: NSB For personal use only Contact Nathan Smith Dr Anton Uvarov Chief Executive Officer Founding Non-Executive Director +61 477 738 404 +61 8 6268 2641 nsmith@neuroscientific.com au@neuroscientific.com 13
Slide 14: Appendix
For personal use only Appendix ASX: NSB 14
Slide 15: FY2026 - Announcements & News Flow
FY2026 - Announcements & News Flow Key Announcements from Q1, Q2, and Q3 of FY2026 25/07/2025 Dr Catherine Cole Appointed as Chief Medical Officer Dr Catherine Cole, esteemed clinician and regulatory expert, to guide MSC therapies 28/07/2025 Experienced Cell Therapy Executive Appointed CEO Mr Nathan
NeuroScientific Biopharmaceuticals — JMM Investor Lunch February 2026 on 6ix